These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24975040)

  • 1. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
    Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
    Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
    Wang L; Chen YZ; Shi D; Shi XY; Zou Z; Zhao JH
    Drugs R D; 2011 Dec; 11(4):317-26. PubMed ID: 22133387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
    Funakoshi T; Suzuki M; Tamura K
    Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis.
    Zhang D; Ye J; Xu T; Xiong B
    J Chemother; 2013 Jun; 25(3):170-5. PubMed ID: 23783142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
    Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
    Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of serious neutropenic events in cancer patients treated with bevacizumab: a meta-analysis.
    Zhou F; Shao JH; Wu LQ; Yin XB; Yu X
    Asian Pac J Cancer Prev; 2013; 14(4):2453-9. PubMed ID: 23725157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.